Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Background: Novel targets in neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are needed to improve outcome. The presence of O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation in NETs and NECs may act as a predictive marker for response on treatment with temozolomide...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiddinga, Birgitta, Zwaenepoel, Karen, Janssens, Annelies, Van Meerbeeck, Jan, Pauwels, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159705/
https://www.ncbi.nlm.nih.gov/pubmed/35677534
http://dx.doi.org/10.18632/oncotarget.28240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159705/
https://www.ncbi.nlm.nih.gov/pubmed/35677534
http://dx.doi.org/10.18632/oncotarget.28240

Ejemplares similares